| Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: a real‐world data analysis S Colosimo, F Ravaioli, ML Petroni, L Brodosi, F Marchignoli, FA Barbanti, ... Liver International 41 (4), 731-742, 2021 | 35 | 2021 |
| Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent S Colosimo, GD Tan, ML Petroni, G Marchesini, JW Tomlinson Nutrition, Metabolism and Cardiovascular Diseases 33 (3), 640-648, 2023 | 14 | 2023 |
| Hybrid Closed-Loop Therapy in Adults With Type 1 Diabetes and Above-Target HbA1c: A Real-world Observational Study TSJ Crabtree, TP Griffin, YW Yap, P Narendran, G Gallen, N Furlong, ... Diabetes Care 46 (10), 1831-1838, 2023 | 12 | 2023 |
| Combination of GLP‐1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study ML Petroni, L Montesi, S Colosimo, MT Caletti, A Mazzotti, G Marchesini Endocrinology, Diabetes & Metabolism 2 (4), e00082, 2019 | 10 | 2019 |
| Long‐term follow‐up of web‐based and group‐based behavioural intervention in NAFLD in a real world clinical setting ML Petroni, S Colosimo, L Brodosi, A Armandi, F Bertini, D Montesi, ... Alimentary Pharmacology & Therapeutics 59 (2), 249-259, 2024 | 8 | 2024 |
| Bile acids as drivers and biomarkers of hepatocellular carcinoma S Colosimo, JW Tomlinson World Journal of Hepatology 14 (9), 1730, 2022 | 8 | 2022 |
| Insulin resistance and metabolic flexibility as drivers of liver and cardiac disease in T2DM S Colosimo, SK Mitra, T Chaudhury, G Marchesini Diabetes Research and Clinical Practice, 111016, 2023 | 7 | 2023 |
| Onset and mortality of Parkinson’s disease in relation to type II diabetes G Pezzoli, E Cereda, P Amami, S Colosimo, M Barichella, G Sacilotto, ... Journal of Neurology 270 (3), 1564-1572, 2023 | 6 | 2023 |
| Use of branched-chain amino acids as a potential treatment for improving nutrition-related outcomes in advanced chronic liver disease S Colosimo, S Bertoli, F Saffioti Nutrients 15 (19), 4190, 2023 | 4 | 2023 |
| should NAFLD be included in the definition of Metabolic Syndrome? S Colosimo, G Marchesini Alimentary Pharmacology & Therapeutics 57 (10), 1151-1152, 2023 | 3 | 2023 |
| Metformin and the Liver: Unlocking the Full Therapeutic Potential F Perazza, L Leoni, S Colosimo, A Musio, G Bocedi, M D’Avino, G Agnelli, ... Metabolites 14 (4), 186, 2024 | 2 | 2024 |
| Supplementation with Anti-inflammatory Nutraceutical Products in the Management of Chronic Pelvic Pain: A Narrative Review. S Colosimo, E Balzani, RM Cioni, M Campesato, AFG Cicero Current Topics in Nutraceutical Research 20 (2), 2022 | 1 | 2022 |
| A novel model for predicting diabetes remission after bariatric surgery based on the measurement of C-peptide and creatinine in serum: A pilot study S Colosimo, MA Martínez-Sánchez, A Balaguer-Román, ... Nutrition, Metabolism and Cardiovascular Diseases 34 (5), 1142-1145, 2024 | | 2024 |
| Does knowledge about liver disease enhance adherence to lifestyle recommendations? Authors' reply ML Petroni, S Colosimo, G Marchesini Alimentary Pharmacology & Therapeutics 59 (2), 285-286, 2024 | | 2024 |
| The role of glycated haemoglobin in predicting disease severity in non-alcoholic fatty liver disease S Colosimo, H Miller, D Koutoukidis, T Marjot, G Tan, D Harman, G Aithal, ... Endocrine Abstracts 94, 2023 | | 2023 |
| Developing a risk stratification tool for advanced NAFLD fibrosis using routinely measured clinical variables in a diabetes clinic annual review H Miller, S Colosimo, W Li, J Cobbold, W Alazawi, D Harman, G Aithal, ... Journal of Hepatology 78, S708, 2023 | | 2023 |
| Optimization of glucose control drives improvement of NAFLD independent of weight loss in people with T2D: Selected Abstract–Spring Meeting 2023 S Colosimo, GD Tan, ML Petroni, S Bertoli, G Marchesini, JW Tomlinson European Atherosclerosis Journal 2 (1), 21-21, 2023 | | 2023 |
| Can improved glycaemic control improve NAFLD independent of weight loss in patients with type 2 diabetes? S Colosimo, G Tan, G Marchesini, J Tomlinson Endocrine Abstracts 86, 2022 | | 2022 |
| WJCC NJ Xiao, TT Cui, F Liu, W Li, ZX Yu, W Yang, WS Yin, KX Peng, YL Pan, ... World 10 (23), 8057-8431, 2022 | | 2022 |
| 182-LB: Delayed Onset of Parkinson’s Disease among Type 2 Diabetes Subjects—Data from an Observational Study S Colosimo, E Cereda, F Del Sorbo, D Calandrella, M Barichella, ... Diabetes 71 (Supplement_1), 2022 | | 2022 |
Giulio MarchesiniProfessor of Medicine, University of Bologna在 unibo.it 的电子邮件经过验证
